Inflammation 200914 May 2009 GlaxoSmithKline, Stevenage Organised by RSC BMCS CIRCULAR now available, see below |
 |
The objective of the meeting is to bring together scientists with an interest in inflammation research, to encourage communication and discussion of recent advances in the development of new therapies for the wide diversity of serious diseases with underlying inflammatory processes. The meeting will be opened by a plenary lecture providing a perspective on the challenges in inflammation research followed by individual case studies targeting a variety of inflammatory mechanisms.
Speakers will include
|
Plenary lecture:
Perspectives on challenges in inflammation research Professor Moira Whyte (University of Sheffield) |
|
Allosteric modulation of
receptors involved in inflammation Laurent Galibert (Addex Pharmaceuticals) |
|
Adventures in Syk
inhibition Vipul Patel (GlaxoSmithKline) |
|
Discovery
and optimization of a series of CCR4 antagonists
from hit to CD David Cheshire (AstraZeneca) |
|
FLAP
inhibitors for the treatment of inflammatory diseases: The development
of AM103 John Hutchinson (Amira Pharmaceuticals) |
|
The discovery of
potent, orally bioavailable heterocyclic derivatives as CXCR2 antagonists David Porter (Novartis) |
|
PI3Kgamma
inhibitors - Aspirins of the 21st century? Thomas Ruckle (Merck Serono) |
|
The role of
Sphingosine-1-phosphate receptor modulator in the prevention of
transplant rejection and autoimmune disease Frederic Zecri (Novartis) |
Further Information
Full details are in the Circular and Application Form. Please click here to open the PDF file.